Trial · NCT06596642
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 28
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Red Blood Cell (RBC) transfusion units received by participants | Baseline, every 3 weeks thereafter until week 96 | |
| Primary | Participant hemoglobin (Hb) level results | Baseline, every 3 weeks thereafter until week 96 | |
| Primary | Participant serum ferritin results | Baseline, week 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Participant platelet level results | Baseline, and every 3 weeks thereafter up to week 96 | |
| Secondary | Participant white blood cell count results | Baseline, and every 3 weeks thereafter up to week 96 | |
| Secondary | Participant reticulocytes/normoblast count results | Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Participant Hemoglobin F (HbF) levels | Baseline and weeks 6 and 12 | |
| Secondary | Participant uric acid level results | Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Participant lactate dehydrogenase (LDH) level results | Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Participant aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio | Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Participant creatinine level results | Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Participant bilirubin (total and direct) laboratory values | Baseline, and weeks 12, 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Type of iron chelating therapy prescribed to participants | Baseline, every 3 weeks thereafter until week 96 | |
| Secondary | Iron chelating therapy treatment dosage prescribed to participants | Baseline, every 3 weeks thereafter until week 96 | |
| Secondary | Participant Adverse Events (AEs) | Baseline and every 3 weeks until week 12, then weeks 24, 36, 48, 60, 72, 84 and 96 | |
| Secondary | Participant health-related quality of life as assessed by Transfusion-dependent Quality of Life (TranQoL) questionnaire | Baseline, week 12, 24, 48, 72 and 96 | |
| Secondary | Participant health-related quality of life as assessed by EQ-5D-5L questionnaire | Baseline, week 12, 24, 48, 72 and 96 | |
| Secondary | Luspatercept treatment dosage prescribed to participants | Baseline, every 3 weeks thereafter until week 96 | |
| Secondary | Duration of luspatercept treatment | Baseline, every 3 weeks thereafter until week 96 | |
| Secondary | Participant reason(s) for luspatercept treatment discontinuation as assessed by the treating clinician | Baseline, every 3 weeks thereafter until week 96 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06596642/registered